-
Court Denies Amgen Motion to Dismiss in Etanercept Antitrust Case
07 Oct 2025 17:49 GMT
… Americans,” alleges that Amgen has “unlawfully delay[ed] competition for its blockbuster … competition from biosimilars. To “shore up its defenses to this threat,” Amgen … exclusive licensee and enabling Amgen to “exclude competitors from the etanercept market …
-
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
06 Oct 2025 21:42 GMT
… From the List Price Amgen (NASDAQ: AMGN) today announced the … full Prescribing Information. About Amgen
Amgen discovers, develops, manufactures … recently launched products, competition from other products including … or circumvented by our competitors, or we may …
-
Amgen’s Phase III data supports FDA label expansion of Repatha
03 Oct 2025 14:26 GMT
… predicts this will dent Amgen’s market dominance, with …
Repatha’s main market competition comes from Praluent (alirocumab … Regeneron and Sanofi, and Amgen were embroiled in a … therapies, with Amgen emerging victorious.
Amgen also faces competition from Novartis …
-
Amgen claims ‘landmark’ study result that could widen heart drug’s use
02 Oct 2025 20:55 GMT
… latest study results — which Amgen referred to as a “landmark … has still become one of Amgen’s most lucrative products, … boost sales beforehand, though, if Amgen can quickly turn them into …
Repatha could also soon face competition from an oral PCSK9 blocker …
-
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
26 Sep 2025 13:33 GMT
… /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced a $650 million … Carolina, respectively.
About Amgen
Amgen discovers, develops, manufactures … recently launched products, competition from other products … or circumvented by our competitors, or we may …
-
Amgen Expands US Manufacturing Network Amid New Tariff Policy
26 Sep 2025 18:48 GMT
… pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 … Manufacturers From ‘Unfair Outside Competition’
It is expected to … chief executive officer at Amgen.
Puerto Rico Governor …
In May, Sanofi SA (NASDAQ: SNY), another European company …
-
Amgen Fires Back with Counterclaims in Aflibercept BPCIA Litigation
25 Sep 2025 22:54 GMT
… of unfair competition under California law.
Prosecution Laches: Amgen argues that … s anticompetitive conduct.”
Unfair Competition: Finally, in Amgen’s eighth counterclaim, it … conduct “violates California’s Unfair Competition Law, Cal. Bus. & …
-
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
17 Oct 2025 22:14 GMT
… Characterized by Epithelial-Driven Inflammation Amgen (NASDAQ:AMGN) and AstraZeneca today announced that … of recently launched products, competition from other products including biosimilars … invalidated or circumvented by our competitors, or we may fail to …
-
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
09 Sep 2025 04:12 GMT
… 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., … regulatory authority. About Amgen
Amgen discovers, develops, manufactures … recently launched products, competition from other products including … or circumvented by our competitors, or we may …
-
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
09 Sep 2025 02:56 GMT
… /PRNewswire/ — Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd … regulatory authority.
About Amgen
Amgen discovers, develops, manufactures … recently launched products, competition from other products … or circumvented by our competitors, or we may …
About
© 1995-2025